Clinical Trial Update: A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating sibutramine with extended-release topiramate in adults with overweight/obesity has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Sibutramine (sibutramine)
• Topiramate XR (topiramate)

Snippet

Sponsor: Eurofarma Laboratorios S.A. | Conditions: Overweight, Obesity | Phase 3 | Status: WITHDRAWN